Report
Luis Arredondo
EUR 50.00 For Business Accounts Only

ROVI: LA FDA RETRASA LA APROBACIÓN DE RISVAN (ANÁLISIS BANCO SABADELL)

En relación con el proceso de aprobación regulatoria de Risvan (Risperidona ISM en EE.UU.), acaba de anunciar que la FDA le ha comunicado que debe cerrar las observaciones realizadas por la propia FDA durante su inspección de mayo’23.
Underlying
Laboratorios Farmaceuticos Rovi S.A.

Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.

Provider
Sabadell
Sabadell

Analysts
Luis Arredondo

Other Reports on these Companies
Other Reports from Sabadell

ResearchPool Subscriptions

Get the most out of your insights

Get in touch